These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 36654091)

  • 1. Effect of sacubitril/valsartan on inflammation and oxidative stress in doxorubicin-induced heart failure model in rabbits.
    Yu C; Li D; Li Z; Yu D; Zhai G
    Acta Pharm; 2021 Sep; 71(3):473-484. PubMed ID: 36654091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin receptor-neprilysin inhibition by sacubitril/valsartan attenuates doxorubicin-induced cardiotoxicity in a pretreatment mice model by interfering with oxidative stress, inflammation, and Caspase 3 apoptotic pathway.
    Dindaş F; Güngör H; Ekici M; Akokay P; Erhan F; Doğduş M; Yılmaz MB
    Anatol J Cardiol; 2021 Nov; 25(11):821-828. PubMed ID: 34734816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sacubitril/valsartan attenuated myocardial inflammation, fibrosis, apoptosis and promoted autophagy in doxorubicin-induced cardiotoxicity mice via regulating the AMPKα-mTORC1 signaling pathway.
    Hu F; Yan S; Lin L; Qiu X; Lin X; Wang W
    Mol Cell Biochem; 2024 Sep; ():. PubMed ID: 39304614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF.
    Myhre PL; Prescott MF; Murphy SP; Fang JC; Mitchell GF; Ward JH; Claggett B; Desai AS; Solomon SD; Januzzi JL
    JACC Heart Fail; 2022 Feb; 10(2):119-128. PubMed ID: 35115085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in
    Myakala K; Jones BA; Wang XX; Levi M
    Am J Physiol Renal Physiol; 2021 Jun; 320(6):F1133-F1151. PubMed ID: 33870733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction.
    Mohebi R; Liu Y; Piña IL; Prescott MF; Butler J; Felker GM; Ward JH; Solomon SD; Januzzi JL
    J Am Coll Cardiol; 2022 Oct; 80(16):1529-1541. PubMed ID: 36229089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined levosimendan and Sacubitril/Valsartan markedly protected the heart and kidney against cardiorenal syndrome in rat.
    Sung PH; Chai HT; Yang CC; Chiang JY; Chen CH; Chen YL; Yip HK
    Biomed Pharmacother; 2022 Apr; 148():112745. PubMed ID: 35202913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of sacubitril/valsartan on cardiac function in heart failure rabbits with preserved ejection fraction].
    Gao SY; Yao DH; Li JF; Xie QM; Jiang SC
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):887-893. PubMed ID: 31744278
    [No Abstract]   [Full Text] [Related]  

  • 9. Effectiveness and safety of sacubitril/valsartan for patients with hypertension and heart failure in the real-world setting: A retrospective study in China.
    Zuo C; Li X; Fan L; Li J; Tian D; Chen C; Li X; Lv Q
    J Clin Pharm Ther; 2022 Oct; 47(10):1539-1547. PubMed ID: 35649528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload.
    Nordén ES; Bendiksen BA; Andresen H; Bergo KK; Espe EK; Hasic A; Hauge-Iversen IM; Veras I; Hussain RI; Sjaastad I; Christensen G; Cataliotti A
    ESC Heart Fail; 2021 Apr; 8(2):918-927. PubMed ID: 33497525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study of the sequential treatment of acute heart failure with sacubitril/valsartan by recombinant human brain natriuretic peptide: A randomized controlled trial.
    Pang Z; Pan C; Yao Z; Ren Y; Tian L; Cui J; Liu X; Zhang L; Chen Y
    Medicine (Baltimore); 2021 Apr; 100(16):e25621. PubMed ID: 33879733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sacubitril/Valsartan Averts Adverse Post-Infarction Ventricular Remodeling and Preserves Systolic Function in Rabbits.
    Torrado J; Cain C; Mauro AG; Romeo F; Ockaili R; Chau VQ; Nestler JA; Devarakonda T; Ghosh S; Das A; Salloum FN
    J Am Coll Cardiol; 2018 Nov; 72(19):2342-2356. PubMed ID: 30384891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.
    Myhre PL; Vaduganathan M; Claggett B; Packer M; Desai AS; Rouleau JL; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
    J Am Coll Cardiol; 2019 Mar; 73(11):1264-1272. PubMed ID: 30846338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat.
    Habibi J; Aroor AR; Das NA; Manrique-Acevedo CM; Johnson MS; Hayden MR; Nistala R; Wiedmeyer C; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2019 Mar; 18(1):40. PubMed ID: 30909895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sacubitril/valsartan decreases mortality in the rat model of the isoprenaline-induced takotsubo-like syndrome.
    Ali A; Redfors B; Alkhoury J; Oras J; Henricsson M; Boren J; Björnson E; Espinosa A; Levin M; Gan LM; Omerovic E
    ESC Heart Fail; 2021 Oct; 8(5):4130-4138. PubMed ID: 34463049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.
    Nougué H; Pezel T; Picard F; Sadoune M; Arrigo M; Beauvais F; Launay JM; Cohen-Solal A; Vodovar N; Logeart D
    Eur J Heart Fail; 2019 May; 21(5):598-605. PubMed ID: 30520545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sacubitril/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation.
    Li LY; Lou Q; Liu GZ; Lv JC; Yun FX; Li TK; Yang W; Zhao HY; Zhang L; Bai N; Zhan CC; Yu J; Zang YX; Li WM
    Eur J Pharmacol; 2020 Aug; 881():173120. PubMed ID: 32325147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of Sacubitril/Valsartan on pulmonary hypertension in hemodialysis patients.
    Zhao C; Guo Y; Wang Y; Wang L; Yu L; Liang Y; Zhai Z; Tang L
    Front Med (Lausanne); 2022; 9():1055330. PubMed ID: 36523777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril/valsartan in Germany.
    Wachter R; Viriato D; Klebs S; Grunow SS; Schindler M; Engelhard J; Proenca CC; Calado F; Schlienger R; Dworak M; Balas B; Bruce Wirta S
    Postgrad Med; 2018 Apr; 130(3):308-316. PubMed ID: 29446691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sacubitril/Valsartan Inhibits Cardiomyocyte Hypertrophy in Angiotensin II-Induced Hypertensive Mice Independent of a Blood Pressure-Lowering Effect.
    Tashiro K; Kuwano T; Ideishi A; Morita H; Idemoto Y; Goto M; Suematsu Y; Miura SI
    Cardiol Res; 2020 Dec; 11(6):376-385. PubMed ID: 33224383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.